VRTX Technical Analysis
As of date:9/24/2021
VRTX stock price:183.61
VRTX 50 DMA:195.49
VRTX 200 DMA:210.27
VRTX MACD (200-50):14.78
VRTX RSI:21.00
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)21.00
Extremely
Oversold

Also see:
VRTX Market Cap History
VRTX Shares Outstanding History
VRTX YTD Return

Try ChartSweeps today
Quotes delayed 20 minutes
Get Free SEC filing alerts for VRTX:
VRTX SEC Filing Email Alerts ServiceExternal link

FMBI Crosses Above Key Moving Average Level
20 minutes ago


Atlantic Union Bankshares Breaks Above 200-Day Moving Average - Bullish for AUB
21 minutes ago


Bullish Two Hundred Day Moving Average Cross - TCX
21 minutes ago


Bullish Two Hundred Day Moving Average Cross - SRCL
22 minutes ago


Notable Two Hundred Day Moving Average Cross - PRTH
22 minutes ago


GABC Makes Bullish Cross Above Critical Moving Average
1 hour, 16 minutes ago


Bullish Two Hundred Day Moving Average Cross - EB
1 hour, 23 minutes ago


Bullish Two Hundred Day Moving Average Cross - WTTR
1 hour, 25 minutes ago


BALY Makes Bullish Cross Above Critical Moving Average
1 hour, 25 minutes ago


Bullish Two Hundred Day Moving Average Cross - GOOS
1 hour, 27 minutes ago


Notable Two Hundred Day Moving Average Cross - GGM
1 hour, 27 minutes ago


PennyMac Financial Services Breaks Below 200-Day Moving Average - Notable for PFSI
1 hour, 27 minutes ago


Notable Two Hundred Day Moving Average Cross - CCI
1 hour, 29 minutes ago


Notable Two Hundred Day Moving Average Cross - HMOP
1 hour, 29 minutes ago


Invesco Municipal Income Opportunities Trust (OIA) Shares Cross Below 200 DMA
1 hour, 29 minutes ago


More Technical Analysis News

VRTX Technical AnalysisVRTX RSI
Vertex Pharmaceuticals develops and commercializes therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. Co.'s marketed products are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is co-developing CTX001, an investigational CRISPR/Cas9-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia.

When researching a stock like Vertex Pharmaceuticals, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from VRTX Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for VRTX stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
VRTX DMAVRTX MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Vertex Pharmaceuticals (VRTX) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

WAT Technical Analysis
WCG Technical Analysis
XRAY Technical Analysis
ZBH Technical Analysis
ZTS Technical Analysis
A Technical Analysis
ABBV Technical Analysis
ABC Technical Analysis
ABMD Technical Analysis
ABT Technical Analysis
More Healthcare companies »

 

VRTX Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2021, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.